Symphony Technology Group Acquires Source Healthcare Analytics from Wolters Kluwer nv; Will Combine With ImpactRx, Inc., TargetRx, Inc. and AlphaDetail, Inc. to Create Symphony Health Solutions
“The healthcare ecosystem is undergoing dramatic change,” said Dr. Romesh Wadhwani, Chairman and CEO of STG. “We believe it is critical for major participants in the industry to transform their commercial approaches informed by analysis and insight, and they need innovation from their service providers to drive change. With Symphony Health Solutions, we will create a high-value, high-impact organization focused on the healthcare industry that will help customers dramatically improve their performance, productivity and profitability.”
Source Healthcare Analytics (SHA) pioneered the physician-level targeting environment that pharmaceutical companies use today, providing strategic market data that analyzes the industry from the perspectives of providers, payers and patients to a variety of private and public organizations. ImpactRx, an STG portfolio company since April 2011, provides the biopharmaceuticals industry with insights into the impact of promotion on physicians’ attitudes and prescribing behavior. During the last year, ImpactRx expanded its breadth of solutions with the acquisitions of TargetRx and AlphaDetail, to become the leading provider of promotional effectiveness solutions to the industry.
These four businesses will come together under Symphony Health Solutions. The businesses will be integrated over time, beginning with offering strong joint value propositions for clients. The current leaders of the businesses, Greg Ellis, President and CEO, ImpactRx; Bob Jansen, President Source Commercial & GM and Michelle Woker, President Source Operations, will continue in their respective roles.
“Our strategic intent when we acquired ImpactRx a year ago was to build a differentiated solutions company in life sciences capable of delivering compelling value through insights informed by data,” said J.T. Treadwell, Managing Director with STG. “By taking this step, and building upon our earlier acquisitions of TargetRx and AlphaDetail, we have greatly accelerated our ability to deliver comprehensive value across a range of commercial decisions, and deliver patient centric insights at a unique scale. We are very enthusiastic for the next phase.”
“Biopharmaceutical companies are facing increasingly complex challenges regarding how to most effectively allocate resources across all stages of the life cycle, and commercial models that worked a decade ago are increasingly less useful,” said Gregory Ellis, President and CEO of ImpactRx. “Our vision is simple: to transform biopharmaceutical marketing through delivery of enhanced information, analytics and solutions that integrate across patients, prescribers and payers, as well as promotional activity.”
“We are thrilled to be a part of the larger Symphony Health Solutions vision,” said Bob Jansen. “STG is a strong technology and innovation-driven investor, and they are a uniquely-suited partner for us to continually grow our value proposition.” Michelle Woker noted, “Bringing together SHA’s world-class secondary data assets with ImpactRx’s proprietary syndicated data set and analytical and therapeutic expertise will enable our combined new company to deliver the comprehensive, multi-channel solutions our clients need.”
About Source Healthcare Analytics
Source Healthcare Analytics (Phoenix, AZ) is a leading provider of information and analytics to the pharmaceutical, biotech and financial industries. The company’s brands include Source®, ProMetis™ and inThought™. A longstanding provider of market data and healthcare analytics, Source offers a unique set of comprehensive patient and physician-level prescribing and usage data. ProMetis provides a three-dimensional market view of prescriber, patient and payer activity in a breakthrough, integrated platform. Led by a team of industry veterans with extensive sell-side research experience, inThought delivers actionable market research reports read by pharmaceutical and healthcare professionals worldwide.
About ImpactRx and AlphaDetail
ImpactRx is the leading provider of consultative and analytically-based commercial effectiveness solutions to the healthcare industry. Powered by its longitudinal and normative data assets, ImpactRx’s consulting analytics and custom research capabilities provide unparalleled insight into the dynamics of the biopharmaceutical marketplace. Through its i-enabled network of more than 4,000 targeted physicians and its proprietary, state-of-the-art research technology, ImpactRx captures not only physician treatment decisions in response to promotion, but also the attitudes, perceptions and beliefs underlying those decisions. The integration of its comprehensive behavioral and attitudinal data with its innovative consulting analytics, global research expertise and therapeutic knowledge enables ImpactRx to deliver breakthrough solutions to its clients. These solutions empower clients to improve brand performance by making more informed and effective decisions around marketing strategy, field and channel execution and pre-launch and launch planning. AlphaDetail is a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry’s strongest foundations that include a team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our clients’ most challenging questions. For more information, visit: www.impactrx.com and www.alphadetail.com.
About Symphony Technology Group
Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and being a partner in building great software and services companies. In addition to capital, STG provides transformation expertise to enable its portfolio companies to deliver more value to clients to retain and attract the best talent, and to achieve best-in-class business performance. All STG portfolio companies are expected to grow through innovation. STG’s current portfolio consists of 15 global companies with combined revenue of $2.5 Billion, and 15,000 employees spread evenly across North America, Europe and Asia. For more information, visit: www.symphonytg.com
Thomas M. Kivett
Managing Director
Kivett & Company Communications, LLC
332 West 19th Street, Suite 2A
New York, NY 10011
phone: (212) 727-2935
fax: (212) 727-2552
email: tkivett@kivettandco.com
www.kivettandco.com